Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1974 1
1980 1
1982 1
1983 2
1986 1
1987 1
1989 1
1990 1
1991 1
1992 3
1994 8
1995 1
1996 2
1997 4
1998 1
1999 2
2000 1
2001 3
2002 3
2003 1
2004 1
2005 2
2006 2
2007 2
2008 1
2009 1
2011 1
2012 1
2014 2
2016 1
2017 2
2018 1
2020 1
2021 1
2022 7
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. Among authors: swanson cj. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. Swanson CJ, et al. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. Alzheimers Res Ther. 2021. PMID: 33865446 Free PMC article. Clinical Trial.
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. McDade E, et al. Among authors: swanson cj. Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2. Alzheimers Res Ther. 2022. PMID: 36544184 Free PMC article. Clinical Trial.
Viral Aggregation: The Knowns and Unknowns.
Pradhan S, Varsani A, Leff C, Swanson CJ, Hariadi RF. Pradhan S, et al. Among authors: swanson cj. Viruses. 2022 Feb 21;14(2):438. doi: 10.3390/v14020438. Viruses. 2022. PMID: 35216031 Free PMC article. Review.
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ, Li D, Krause S, Rissman RA, Walter S, Raman R, Johnson KA, Aisen PS. Rafii MS, et al. Among authors: swanson cj. Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15. Alzheimers Dement. 2023. PMID: 35971310 Free PMC article.
The GCaMP-R Family of Genetically Encoded Ratiometric Calcium Indicators.
Cho JH, Swanson CJ, Chen J, Li A, Lippert LG, Boye SE, Rose K, Sivaramakrishnan S, Chuong CM, Chow RH. Cho JH, et al. Among authors: swanson cj. ACS Chem Biol. 2017 Apr 21;12(4):1066-1074. doi: 10.1021/acschembio.6b00883. Epub 2017 Mar 1. ACS Chem Biol. 2017. PMID: 28195691 Free PMC article.
67 results